Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E18.68 EPS (ttm)3.34 Insider Own0.10% Shs Outstand1.62B Perf Week1.86%
Market Cap101.18B Forward P/E10.80 EPS next Y5.77 Insider Trans-1.52% Shs Float1.60B Perf Month5.09%
Income5.48B PEG1.08 EPS next Q1.20 Inst Own72.60% Short Float1.40% Perf Quarter10.89%
Sales23.78B P/S4.26 EPS this Y185.20% Inst Trans2.36% Short Ratio3.18 Perf Half Y1.87%
Book/sh2.45 P/B25.44 EPS next Y18.89% ROA- Target Price70.83 Perf Year1.13%
Cash/sh- P/C- EPS next 5Y17.24% ROE- 52W Range44.55 - 69.54 Perf YTD7.36%
Dividend2.28 P/FCF- EPS past 5Y3.50% ROI16.90% 52W High-10.35% Beta1.49
Dividend %3.66% Quick Ratio- Sales past 5Y7.90% Gross Margin79.80% 52W Low39.93% ATR1.31
Employees28000 Current Ratio- Sales Q/Q18.20% Oper. Margin34.20% RSI (14)69.80 Volatility1.84% 2.11%
OptionableYes Debt/Eq- EPS Q/Q31.10% Profit Margin23.00% Rel Volume1.21 Prev Close61.46
ShortableYes LT Debt/Eq- EarningsApr 28 BMO Payout47.40% Avg Volume7.08M Price62.34
Recom2.10 SMA203.51% SMA508.02% SMA2007.63% Volume8,624,300 Change1.43%
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-06-16 12:11AM  [$$] Knockoffs of Biotech Drugs Bring Paltry Savings at The Wall Street Journal
May-05-16 05:13PM  Charts are bullish for health care: Technician Yahoo Finance
10:28AM  [$$] Biotech Drug Knockoffs Bring Paltry Savings at The Wall Street Journal
May-04-16 08:41PM  Sohn Investment Conference 2016 Full Wrap Up Yahoo Finance Contributors
01:11PM  Biotech Stock Roundup: Amgen Impresses, Gilead Disappoints in Q1, Biogen to Spin Off Hemophilia Zacks
10:05AM  Gilead Sciences: Feeling the Competitive Burn? at Barrons.com
May-03-16 01:40PM  What Do Analysts Recommend for AbbVie? Market Realist
01:40PM  How Does AbbVies Valuation Compare to Its Peers? Market Realist
01:25PM  ETFs with exposure to AbbVie, Inc. : May 3, 2016 at Capital Cube
09:09AM  AbbVies Viekira Pak Saw Weaker-than-Expected Performance Market Realist
May-02-16 12:38PM  Gilead: What's Your Long Term Thesis? Yahoo Finance Contributors
11:32AM  Humira Continues to Be a Strong Growth Driver for AbbVie in 1Q16 Market Realist
11:31AM  How Did AbbVie Perform in 1Q16? Market Realist
10:38AM  AbbVie, Inc. :ABBV-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
Apr-29-16 05:51PM  ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, R EDGAR Online
05:22PM  Worst may be over for embattled pharma Yahoo Finance Contributors
04:50PM  AbbVie (ABBV) Stock Price Target Hiked at Jefferies at TheStreet
12:32PM  Pharma stocks to bet on CNBC
11:12AM  AbbVie Gets European Medicines Agency's Positive Opinion For Its IMBRUVICA Benzinga
10:50AM  AbbVie Doubles Down on M&A at Bloomberg
09:18AM  European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients PR Newswire
08:00AM  AbbVie to Present at the Bank of America Merrill Lynch 2016 Global Health Care Conference PR Newswire
07:39AM  Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA (Daclizumab) for Treatment of Multiple Sclerosis Business Wire
07:26AM  Biogen, AbbVie multiple sclerosis drug wins EU green light Reuters
01:02AM  Galapagos and AbbVie expand their cystic fibrosis collaboration GlobeNewswire
12:38AM  [$$] Drugmakers Place Big Bets on Cancer Medicines at The Wall Street Journal
12:38AM  [$$] Abbott Agrees to Buy St. Jude in $25 Billion Deal at The Wall Street Journal
Apr-28-16 07:13PM  [$$] Abbott Agrees to Buy St. Jude in $25 Billion Deal at The Wall Street Journal
06:26PM  Stemcentrx Sale to Return a Record $1.7 Billion for VC Firm Founders Fund at Bloomberg
05:56PM  Edited Transcript of ABBV earnings conference call or presentation 28-Apr-16 1:00pm GMT Thomson Reuters StreetEvents
05:34PM  [$$] Drugmakers Place Big Bets on Cancer Medicines at The Wall Street Journal
04:50PM  Bay Area cancer-fighting startup acquired for up to $10.2B in blockbuster deal at American City Business Journals
04:43PM  US STOCKS-Wall St sinks on BOJ fears, Icahn comments Reuters
04:23PM  Medical M&A Rules The Day As Abbott, AbbVie Make Buys, Sanofi Bids at Investor's Business Daily
04:05PM  Big Pharma grooves $20 billion M&A dance with 2 Bay Area biotechs at American City Business Journals
03:41PM  US STOCKS-Wall St flounders on BOJ fears as Facebook, M&A boosts wane Reuters
03:25PM  Bay Area biotech: AbbVie buying Stemcentrx for $5.8B; Sanofi bids $9.3B for Medivation at San Jose Mercury News
03:00PM  AbbVie forges deeper into cancer, as clock ticks for Humira Reuters
01:55PM  Jim Cramer: Investors Should Flock to Pharma at TheStreet
01:54PM  AbbVie To Pay $5.8 Bil And Milestones For Stemcentrx, Diluting EPS at Investor's Business Daily
01:41PM  [$$] Three pharma deals worth $45bn reignite M&A boom at Financial Times
01:33PM  AbbVie to buy Stemcentrx in $5.8B cash and stock deal at USA TODAY
01:30PM  Capture A Potential 35% Gain With This Fast-Growing Stock StreetAuthority Network
01:30PM  $40 Billion Takeover Has Big Pharma Giddy at TheStreet
12:38PM  How traders are betting on rally in AbbVie optionMONSTER
12:30PM  Why These 5 Stocks Are Trending Today at Insider Monkey
12:22PM  [$$] AbbVie to Buy Stemcentrx for $5.8B at The Wall Street Journal
10:19AM  [$$] AbbVie joins wave of pharma moves with Stemcentrx deal at Financial Times
10:01AM  AbbVie to buy Stemcentrx in $5.8 billion deal at MarketWatch
09:48AM  AbbVie tops Street 1Q forecasts, buying StemCentrx AP
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead Zacks
09:16AM  AbbVie (ABBV) Beats on 1Q Earnings, Lowers View on Deal Zacks
09:12AM  AbbVie (ABBV) Stock Tumbles, Revises 2016 Outlook to Reflect Stemcentrx Acquisition at TheStreet
09:10AM  Why AbbVie Earnings Failed to Impress Investors at 24/7 Wall St.
09:01AM  AbbVie (ABBV) Tops 1Q Earnings Estimates, Announces Deal Zacks
09:01AM  [$$] AbbVie to Buy Stemcentrx for $5.8 Billion at The Wall Street Journal
09:00AM  AbbVie Inc Conference Call to Discuss Q1 2016 Earnings and the Acquisition of Stemcentrx scheduled for 9:00 am ET today CCBN
08:15AM  AbbVie Q1 EPS Tops Estimates, Updates Full Year EPS Guidance Below Expectations Benzinga
08:05AM  AbbVie to buy Stemcentrx to boost cancer drug portfolio Reuters
07:56AM  AbbVie agrees to buy Peter Thiel-backed biotech Stemcentrx at MarketWatch
07:38AM  AbbVie to buy Stemcentrx in $5.8 bln deal Reuters
07:31AM  AbbVie earnings beats, but offers weak outlook at MarketWatch
07:29AM  AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion at Fortune
07:27AM  ABBVIE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:21AM  AbbVie to Acquire Cancer Drugmaker Stemcentrx for $5.8 Billion at Bloomberg
07:21AM  AbbVie Reports First-Quarter 2016 Financial Results PR Newswire
07:20AM  Hepatitis C drug restrictions in Medicaid eased after Attorney General investigates private insurers at American City Business Journals
07:20AM  AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer PR Newswire
07:07AM  Q1 2016 AbbVie Inc Earnings Release - Before Market Open CCBN
Apr-27-16 10:44PM  [$$] Drug Companies Turning to Startups for New Antibody Technologies at The Wall Street Journal
04:07PM  Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News Zacks
09:47AM  Bulls pile into AbbVie ahead of earnings optionMONSTER
09:15AM  Major Pharma Short Interest Remains Mixed, With 1 Massive Drop at 24/7 Wall St.
09:13AM  Americans still lead the world in something: Use of highly addictive opioids at CNBC
08:21AM  State panel to focus on Hepatitis C drug restrictions in Medicaid after AG reaches agreement with some insurers at American City Business Journals
Apr-26-16 09:30AM  Tipp Hill Cashes Out of Gold Stocks, Puts It Into Healthcare at Insider Monkey
07:16AM  Worried About Social Security? Buy These 4 Stocks at Motley Fool
Apr-25-16 02:42PM  5 Biotech Stocks to Bet on This Earnings Season Zacks
11:50AM  This Big Pharma Stock Is Set to Profit From an Immunology Bonanza at TheStreet
10:53AM  Centene (CNC) Q1 Earnings: Surprise in Store for Stock? Zacks
10:51AM  Aetna (AET) Q1 Earnings: Is a Surprise in Store for Stock? Zacks
09:00AM  AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirr PR Newswire
07:08AM  Big Drug Stocks to Report This Week: LLY, GSK, VRTX, BMY, ABBV Zacks
Apr-23-16 03:16PM  3 Things to Watch in Gilead Sciences, Inc.'s First-Quarter Results at Motley Fool
Apr-22-16 12:27PM  AbbVie (ABBV) Likely to Beat on Q1 Earnings: Stock to Gain? Zacks
Apr-21-16 04:01PM  CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates GlobeNewswire
04:01PM  AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates PR Newswire
09:30AM  The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen Zacks
08:58AM  Better Buy: Pfizer Inc. vs. AbbVie at Motley Fool
01:07AM  AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target PR Newswire
Apr-20-16 04:38PM  Biotech Stock Roundup: Medivation Buyout Rumors Resurface, Synta Up on Merger Deal Zacks
08:30AM  AbbVie, University of Chicago collaborate to advance cancer research PR Newswire
08:25AM  2 Cheap Pharmaceuticals Highlight Jefferies Franchise Picks Dividend Stocks to Buy at 24/7 Wall St.
07:30AM  Data Presented at AAN Highlight Impact of ZINBRYTA (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action Business Wire
07:00AM  AbbVie to Present at the Deutsche Bank 41st Annual Health Care Conference PR Newswire
Apr-19-16 12:19PM  AbbVie trade sees support after earnings
09:06AM  What Do Analysts Recommend for Medivation?
Apr-18-16 11:05AM  Shire Won Patent Infringement Case for Lialda
Apr-17-16 03:02PM  4 Healthcare Stocks That Are Looking Cheap at Motley Fool
Apr-16-16 01:00AM  New AbbVie hepatitis C regimen shows high cure rates -studies
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics, Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schumacher Laura JExecutive Vice PresidentMar 08Sale56.0925,0001,402,341194,138Mar 08 05:23 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Option Exercise22.943,40077,9985,143Feb 09 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Option Exercise35.8865,0002,332,200538,187Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.0924,9791,775,656513,208Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.2440,0212,851,264473,187Jul 31 05:41 PM
HURWICH THOMAS A.VP, ControllerMay 19Option Exercise22.946,200142,23274,660May 21 05:50 PM
HURWICH THOMAS A.VP, ControllerMay 19Sale66.006,200409,20068,460May 21 05:50 PM